{"id":56314,"date":"2026-02-04T23:43:15","date_gmt":"2026-02-04T15:43:15","guid":{"rendered":"https:\/\/flcube.com\/?p=56314"},"modified":"2026-02-04T23:43:16","modified_gmt":"2026-02-04T15:43:16","slug":"pfizer-revenue-drops-2-to-62-6b-amid-covid-decline-non-covid-portfolio-grows","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=56314","title":{"rendered":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows"},"content":{"rendered":"\n<p><strong>Pfizer Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PFE:NYSE\">NYSE:\u202fPFE<\/a>)\u00a0reported full\u2011year 2025 revenue of <strong>USD\u202f62.6\u202fbillion<\/strong>, representing a <strong>2% operational decline<\/strong> at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew <strong>6%<\/strong> for the year and <strong>9%<\/strong> in Q4. The company reaffirmed 2026 guidance of <strong>USD\u202f59.5\u201362.5\u202fbillion<\/strong> despite projected generic headwinds.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-performance-summary\">Financial Performance Summary<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Metric<\/th><th>Q4\u202f2025<\/th><th>Full\u2011Year\u202f2025<\/th><th>YOY Growth (Operational)<\/th><\/tr><\/thead><tbody><tr><td><strong>Total Revenue<\/strong><\/td><td>USD\u202f17.6\u202fB<\/td><td>USD\u202f62.6\u202fB<\/td><td>-2%<\/td><\/tr><tr><td><strong>Pharmaceutical Sales<\/strong><\/td><td>USD\u202f14.84\u202fB<\/td><td>\u2014<\/td><td>-3% (Q4), -2% (FY)<\/td><\/tr><tr><td><strong>Non\u2011COVID Portfolio<\/strong><\/td><td>\u2014<\/td><td>\u2014<\/td><td>+9% (Q4), +6% (FY)<\/td><\/tr><tr><td><strong>2026 Revenue Guidance<\/strong><\/td><td>\u2014<\/td><td>USD\u202f59.5\u201362.5\u202fB<\/td><td>\u2014<\/td><\/tr><tr><td><strong>EPS Guidance (2026)<\/strong><\/td><td>\u2014<\/td><td>USD\u202f2.80\u20133.00<\/td><td>\u2014<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-key-product-sales-performance\">Key Product Sales Performance<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Product<\/th><th>2025 Sales<\/th><th>YOY Growth<\/th><th>Strategic Role<\/th><\/tr><\/thead><tbody><tr><td><strong>Abrysvo (RSV vaccine)<\/strong><\/td><td>USD\u202f481\u202fM<\/td><td>+143%<\/td><td>Vaccine portfolio growth<\/td><\/tr><tr><td><strong>Eliquis (apixaban)<\/strong><\/td><td>USD\u202f2.02\u202fB<\/td><td>+8%<\/td><td>Cardiovascular stable<\/td><\/tr><tr><td><strong>Prevnar family<\/strong><\/td><td>USD\u202f1.7\u202fB<\/td><td>+8%<\/td><td>Established vaccine<\/td><\/tr><tr><td><strong>Vyndaqel (tafamidis)<\/strong><\/td><td>USD\u202f1.7\u202fB<\/td><td>+7%<\/td><td>Rare disease expansion<\/td><\/tr><tr><td><strong>Padcev (enfortumab vedotin)<\/strong><\/td><td>USD\u202f508\u202fM<\/td><td>+15%<\/td><td>Oncology ADC growth<\/td><\/tr><tr><td><strong>Comirnaty<\/strong><\/td><td>USD\u202f2.27\u202fB<\/td><td><strong>-35%<\/strong><\/td><td>COVID vaccine decline<\/td><\/tr><tr><td><strong>Paxlovid<\/strong><\/td><td>USD\u202f218\u202fM<\/td><td><strong>-70%<\/strong><\/td><td>COVID therapeutic slump<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-covid-portfolio-impact-amp-2026-outlook\">COVID Portfolio Impact &amp; 2026 Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>COVID Revenue Decline:<\/strong> Comirnaty and Paxlovid combined contributed <strong>~USD\u202f2.5\u202fB<\/strong> : in 2025 vs. <strong>~USD\u202f8\u202fB<\/strong> : in 2024<\/li>\n\n\n\n<li><strong>2026 COVID Forecast:<\/strong> CFO David Denton expects COVID products to generate <strong>~USD\u202f5\u202fbillion<\/strong> in 2026<\/li>\n\n\n\n<li><strong>Generic Headwinds:<\/strong> <strong>USD\u202f1.5\u202fbillion<\/strong> revenue compression expected from anticipated generic entry in 2026<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-pipeline-amp-strategic-updates\">Pipeline &amp; Strategic Updates<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025 Pivotal Starts:<\/strong> <strong>11<\/strong> pivotal studies initiated<\/li>\n\n\n\n<li><strong>2026 Pipeline:<\/strong> <strong>~20<\/strong> pivotal starts expected, including <strong>10<\/strong> for ultra\u2011long\u2011acting obesity assets from <strong>Metsera<\/strong> and <strong>4<\/strong> for <strong>PF\u201108634404<\/strong> (PD\u20111 x VEGF bispecific) in\u2011licensed from <strong>3SBio<\/strong><\/li>\n\n\n\n<li><strong>Obesity Data:<\/strong> Phase\u202fIIb <strong>Vesper\u20113<\/strong> trial for <strong>PF\u201108653944<\/strong> showed <strong>10\u201312.3%<\/strong> placebo\u2011adjusted weight loss with monthly dosing<\/li>\n\n\n\n<li><strong>ACCELERATE Partnerships:<\/strong> Ongoing oncology collaborations and <strong>YaoPharma<\/strong> peptide therapeutic development<\/li>\n<\/ul>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding revenue projections, pipeline development, and commercial prospects for Pfizer\u2019s portfolio. Actual results may differ due to competitive dynamics, regulatory approvals, and market conditions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<div data-wp-interactive=\"core\/file\" class=\"wp-block-file\"><object data-wp-bind--hidden=\"!state.hasPdfPreview\" hidden class=\"wp-block-file__embed\" data=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Q4-2025-PFE-Earnings-Release.pdf\" type=\"application\/pdf\" style=\"width:100%;height:600px\" aria-label=\"Embed of Q4-2025-PFE-Earnings-Release.\"><\/object><a id=\"wp-block-file--media-f2d68162-c3d2-4f12-913f-e119d2f29b24\" href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Q4-2025-PFE-Earnings-Release.pdf\">Q4-2025-PFE-Earnings-Release<\/a><a href=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/Q4-2025-PFE-Earnings-Release.pdf\" class=\"wp-block-file__button wp-element-button\" download aria-describedby=\"wp-block-file--media-f2d68162-c3d2-4f12-913f-e119d2f29b24\">Download<\/a><\/div>\n","protected":false},"excerpt":{"rendered":"<p>Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant&#8230;<\/p>\n","protected":false},"author":1,"featured_media":56319,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7],"tags":[35,16,13,20,27,31,28,863,86,18,12],"class_list":["post-56314","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","tag-adc-xdc","tag-cancer","tag-covid-19","tag-finance","tag-finanical-reports","tag-generic-drugs","tag-multi-specific-antibodies","tag-nyse-pfe","tag-obesity","tag-pd-1-l1","tag-vaccine"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=56314\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows\" \/>\n<meta property=\"og:description\" content=\"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=56314\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-02-04T15:43:15+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-02-04T15:43:16+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows\",\"datePublished\":\"2026-02-04T15:43:15+00:00\",\"dateModified\":\"2026-02-04T15:43:16+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314\"},\"wordCount\":305,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0408.webp\",\"keywords\":[\"ADC \\\/ XDC\",\"Cancer\",\"COVID-19\",\"Finance\",\"Finanical Reports\",\"Generic drugs\",\"Multi-specific antibodies\",\"NYSE: PFE\",\"Obesity\",\"PD-1\\\/L1\",\"Vaccine\"],\"articleSection\":[\"Company\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56314#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=56314\",\"name\":\"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0408.webp\",\"datePublished\":\"2026-02-04T15:43:15+00:00\",\"dateModified\":\"2026-02-04T15:43:16+00:00\",\"description\":\"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=56314\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0408.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/02\\\/0408.webp\",\"width\":1080,\"height\":608,\"caption\":\"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=56314#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows - Insight, China&#039;s Pharmaceutical Industry","description":"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=56314","og_locale":"en_US","og_type":"article","og_title":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows","og_description":"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.","og_url":"https:\/\/flcube.com\/?p=56314","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-02-04T15:43:15+00:00","article_modified_time":"2026-02-04T15:43:16+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=56314#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=56314"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows","datePublished":"2026-02-04T15:43:15+00:00","dateModified":"2026-02-04T15:43:16+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=56314"},"wordCount":305,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=56314#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","keywords":["ADC \/ XDC","Cancer","COVID-19","Finance","Finanical Reports","Generic drugs","Multi-specific antibodies","NYSE: PFE","Obesity","PD-1\/L1","Vaccine"],"articleSection":["Company"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=56314#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=56314","url":"https:\/\/flcube.com\/?p=56314","name":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=56314#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=56314#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","datePublished":"2026-02-04T15:43:15+00:00","dateModified":"2026-02-04T15:43:16+00:00","description":"Pfizer Inc. (NYSE:\u202fPFE)\u00a0reported full\u2011year 2025 revenue of USD\u202f62.6\u202fbillion, representing a 2% operational decline at constant currency, driven by sharp drops in COVID\u201119 product sales. Excluding Comirnaty and Paxlovid, the non\u2011COVID portfolio grew 6% for the year and 9% in Q4. The company reaffirmed 2026 guidance of USD\u202f59.5\u201362.5\u202fbillion despite projected generic headwinds.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=56314#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=56314"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=56314#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","width":1080,"height":608,"caption":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=56314#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Pfizer Revenue Drops 2% to $62.6B Amid COVID Decline, Non-COVID Portfolio Grows"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/02\/0408.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56314","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=56314"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56314\/revisions"}],"predecessor-version":[{"id":56320,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/56314\/revisions\/56320"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/56319"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=56314"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=56314"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=56314"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}